EVMN

Evommune, Inc.

Price Chart

No historical data available

Latest Quote

$13.23

-0.25 (-1.85%)

Current Price

Previous Close	$13.48
Open	$13.48
Day High	$13.65
Day Low	$12.97
Volume	350,566

Fetched: 2026-08-29T17:38:29

Stock Information

Shares Outstanding	36.29M
Total Debt	$8.63M
Cash Equivalents	$200.79M
Revenue	$10.00M
Net Income	$-94.67M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$480.14M
EPS (TTM)	$-11.61
Exchange	NYQ

🌐 Visit Website

Recent Price History

No history data available. Data will be fetched automatically.

About Evommune, Inc.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

📰 Latest News

No news articles available at the moment. Check back later for updates on EVMN.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31
Revenue
Total Revenue	$13,000,000	-
Operating Revenue	$13,000,000	-
Expenses
Total Expenses	$94,071,000	-
Other Income Expense	$8,878,000	-
Other Non Operating Income Expenses	$-50,000	-
Net Non Operating Interest Income Expense	$3,323,000	-
Operating Expense	$94,071,000	-
General And Administrative Expense	$20,029,000	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-68,870,000	-
Net Interest Income	$3,323,000	-
Interest Income	$3,323,000	-
Normalized Income	$-77,798,000	-
Net Income From Continuing And Discontinued Operation	$-68,870,000	-
Total Operating Income As Reported	$-81,071,000	-
Net Income Common Stockholders	$-68,870,000	-
Net Income	$-68,870,000	-
Net Income Including Noncontrolling Interests	$-68,870,000	-
Net Income Continuous Operations	$-68,870,000	-
Pretax Income	$-68,870,000	-
Interest Income Non Operating	$3,323,000	-
Operating Income	$-81,071,000	-
Per Share
Diluted EPS	$-11.22	$-4.27
Basic EPS	$-11.22	$-4.27
Other
Tax Effect Of Unusual Items	$0	-
Tax Rate For Calcs	$0	-
Normalized EBITDA (Bullshit earnings)	$-88,610,000	-
Total Unusual Items	$8,928,000	-
Total Unusual Items Excluding Goodwill	$8,928,000	-
Reconciled Depreciation	$1,389,000	-
EBITDA (Bullshit earnings)	$-79,682,000	-
EBIT	$-81,071,000	-
Diluted Average Shares	$6,136,636	$16,000,096
Basic Average Shares	$6,136,636	$16,000,096
Diluted NI Availto Com Stockholders	$-68,870,000	-
Otherunder Preferred Stock Dividend	$0	-
Gain On Sale Of Security	$8,928,000	-
Research And Development	$74,042,000	-
Selling General And Administration	$20,029,000	-
Other Gand A	$7,484,000	-
Salaries And Wages	$12,545,000	-

Fetched: 2026-08-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31
Assets
Net Tangible Assets	$205,566,000	-
Total Assets	$224,946,000	-
Total Non Current Assets	$71,468,000	-
Other Non Current Assets	$1,516,000	-
Investmentin Financial Assets	$67,489,000	$0
Current Assets	$153,478,000	-
Other Current Assets	$4,278,000	-
Cash Cash Equivalents And Short Term Investments	$149,200,000	-
Cash And Cash Equivalents	$44,063,000	-
Debt
Total Debt	$1,713,000	$1,022,000
Long Term Debt And Capital Lease Obligation	$1,471,000	$535,000
Current Debt And Capital Lease Obligation	$242,000	-
Liabilities
Total Liabilities Net Minority Interest	$19,380,000	-
Total Non Current Liabilities Net Minority Interest	$1,471,000	-
Current Liabilities	$17,909,000	-
Other Current Liabilities	$364,000	-
Current Deferred Liabilities	$0	-
Payables And Accrued Expenses	$12,369,000	-
Payables	$7,756,000	-
Accounts Payable	$7,756,000	-
Equity
Common Stock Equity	$205,566,000	-
Total Equity Gross Minority Interest	$205,566,000	-
Stockholders Equity	$205,566,000	-
Retained Earnings	$-221,089,000	-
Preferred Securities Outside Stock Equity	$0	-
Other
Ordinary Shares Number	$31,524,093	-
Share Issued	$31,524,093	-
Tangible Book Value	$205,566,000	-
Invested Capital	$205,566,000	-
Working Capital	$135,569,000	-
Capital Lease Obligations	$1,713,000	$1,022,000
Total Capitalization	$205,566,000	-
Additional Paid In Capital	$426,652,000	-
Capital Stock	$3,000	-
Common Stock	$3,000	-
Long Term Capital Lease Obligation	$1,471,000	$535,000
Current Deferred Revenue	$0	-
Current Capital Lease Obligation	$242,000	-
Pensionand Other Post Retirement Benefit Plans Current	$4,934,000	-
Current Accrued Expenses	$4,613,000	-
Investments And Advances	$67,489,000	$0
Held To Maturity Securities	$67,489,000	$0
Net PPE	$2,463,000	-
Accumulated Depreciation	$-1,559,000	$-948,000
Gross PPE	$4,022,000	$2,746,000
Leases	$528,000	$458,000
Construction In Progress	$35,000	$0
Other Properties	$1,469,000	$472,000
Machinery Furniture Equipment	$1,990,000	$1,816,000
Properties	$0	$0
Other Short Term Investments	$105,137,000	-

Fetched: 2026-08-22

Cash Flow Statement (Annual)

Metric	2025-12-31
Free Cash Flow
Free Cash Flow	$-76,676,000
Operating Activities
Operating Cash Flow	$-76,441,000
Cash Flow From Continuing Operating Activities	$-76,441,000
Operating Gains Losses	$-8,928,000
Investing Activities
Capital Expenditure	$-235,000
Investing Cash Flow	$-115,307,000
Cash Flow From Continuing Investing Activities	$-115,307,000
Financing Activities
Issuance Of Capital Stock	$65,228,000
Financing Cash Flow	$220,763,000
Cash Flow From Continuing Financing Activities	$220,763,000
Net Other Financing Charges	$-1,382,000
Net Preferred Stock Issuance	$65,228,000
Preferred Stock Issuance	$65,228,000
Other
Repayment Of Debt	$-373,000
Interest Paid Supplemental Data	$7,000
End Cash Position	$45,478,000
Beginning Cash Position	$16,463,000
Changes In Cash	$29,015,000
Proceeds From Stock Option Exercised	$157,290,000
Net Issuance Payments Of Debt	$-373,000
Net Long Term Debt Issuance	$-373,000
Long Term Debt Payments	$-373,000
Net Investment Purchase And Sale	$-115,072,000
Sale Of Investment	$84,100,000
Purchase Of Investment	$-199,172,000
Net PPE Purchase And Sale	$-235,000
Purchase Of PPE	$-235,000
Change In Working Capital	$-4,119,000
Change In Other Working Capital	$-3,000,000
Change In Other Current Liabilities	$-730,000
Change In Payables And Accrued Expense	$1,981,000
Change In Accrued Expense	$2,818,000
Change In Payable	$-837,000
Change In Account Payable	$-837,000
Change In Prepaid Assets	$-2,370,000
Other Non Cash Items	$-1,769,000
Stock Based Compensation	$5,856,000
Depreciation Amortization Depletion	$1,389,000
Depreciation And Amortization	$1,389,000
Gain Loss On Investment Securities	$-8,928,000
Net Income From Continuing Operations	$-68,870,000

Fetched: 2026-08-22